BSX Q2 2025 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Wed, April 22, 2026 astatine 10:14 AM CDT 44 min read

Image source: The Motley Fool.

Wednesday, July 23, 2025 astatine 8 a.m. ET

• Chairman and Chief Executive Officer — Michael F. Mahoney

• Executive Vice President and Chief Financial Officer — Jonathan R. Monson

• Chief Medical Officer — Kenneth M. Stein

• Vice President, Investor Relations — Lauren Tengler

Mike Mahoney, Chairman and Chief Executive Officer; and Jon Monson, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and John volition beryllium joined by our Chief Medical Officer, Dr. Ken Stein. We issued a property merchandise earlier this greeting announcing our Q2 results, which included reconciliations of the non-GAAP measures. The merchandise arsenic good arsenic reconciliations of the non-GAAP measures utilized successful today's telephone tin beryllium recovered connected the Investor Relations conception of our website. Please enactment that connected the call, operational gross excludes the interaction of overseas currency fluctuations, and integrated gross further excludes definite acquisitions and divestitures for which determination are little than a afloat play of comparable nett sales.

For much information, delight notation to the Q2 fiscal and operational highlights deck, which whitethorn beryllium recovered connected the Investor Relations conception of our website. On this call, each references to income and gross are integrated and comparative maturation is compared to the aforesaid 4th of the anterior year, unless different specified. This telephone contains forward-looking statements regarding, among different things, our fiscal performance, concern plans, merchandise show and development. These statements are based connected our existent beliefs utilizing accusation disposable to america arsenic of today's day and are not intended to beryllium guarantees of aboriginal events oregon performance.

If our underlying assumptions crook retired to beryllium incorrect oregon definite risks oregon uncertainties materialize, existent results could alteration materially from those projected by the forward-looking statements. Factors that whitethorn origin specified differences are discussed successful our periodic reports and different filings with the SEC, including the Risk Factors conception of our astir caller yearly study connected Form 10-K. Boston Scientific disclaims immoderate volition oregon work to update these forward-looking statements, but arsenic required by law. At this point, I'll crook it implicit to Mike.

Michael F. Mahoney: Thanks, Lauren, and convey you, everyone, for joining america today. Our 2nd 4th results outperformed our expectations, led by our Cardiovascular conception closing a phenomenal archetypal fractional to 2025. In 2nd 4th '25, full institution operational income grew 22% and integrated income grew 17%, which exceeds the precocious extremity of our guidance scope of 13% to 15% and acold outpacing our underlying weighted mean marketplace maturation rate. Second 4th adjusted EPS of $0.75 grew 23%, besides exceeding the precocious extremity of our guidance scope of $0.71 to $0.73, inclusive of charges related to the worldwide discontinuation of our ACURATE valve. Second 4th adjusted operating borderline was 27.6%. Turning to our 3rd 4th and our afloat twelvemonth '25 outlook.